Lucid Diagnostics Announced That The American Foregut Society Has Formally Requested That Health Insurance Providers Update Their Medical Policies To Include The EsoGuard Esophageal DNA Test As A Covered Service

Author: Benzinga Newsdesk | August 13, 2024 08:55am

Request for insurance coverage aims to enhance early detection and treatment of esophageal precancer to prevent highly lethal esophageal cancer

NEW YORK, Aug. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that the American Foregut Society (AFS), a leading society of gastroenterologists and surgeons collaborating to improve patient outcomes, including in esophageal disease, has formally requested that health insurance providers update their medical policies to include the EsoGuard® Esophageal DNA test as a covered service.

Posted In: LUCD PAVM